Neuroprotective Role of Withaferin A in Huntington's Disease: Current Evidence and Future Perspectives.

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. Its pathogenesis involves mutant huntingtin aggregation, impaired proteostasis and autophagy, transcriptional dysregulation, mitochondrial dysfunction, oxidative stress, neuroinflammation and progressive neuronal loss. Withaferin A (WA), a steroidal lactone derived from Withania somnifera, has demonstrated antioxidant, anti-inflammatory, proteostasis-modulating and stress-response effects in experimental studies. In a transgenic HD mouse model, WA-induced heat-shock-response activation was associated with reduced mutant huntingtin aggregation and attenuation of selected disease-related abnormalities. In contrast, evidence for nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) activation, autophagy regulation, mitochondrial protection and suppression of inflammatory signaling is derived predominantly from cellular experiments and non-HD neurological or inflammatory models rather than from validated HD models. The direct relevance of these proposed mechanisms to HD therefore remains to be established. No clinical studies have demonstrated the safety or therapeutic efficacy of WA in individuals with HD. Moreover, its bioavailability, pharmacokinetic behavior, optimal dose, long-term toxicity, central nervous system exposure and possible drug interactions remain insufficiently characterized. This review critically evaluates HD-specific and indirect evidence concerning the neuroprotective actions of WA, identifies important methodological and translational limitations and discusses priorities for future investigation. Current evidence supports WA as an experimental compound for further preclinical study rather than as an established or clinically applicable treatment for HD.

Key Findings

• Withaferin A (WA) demonstrated antioxidant, anti-inflammatory, proteostasis-modulating, and stress-response effects in experimental studies related to Huntington's disease (HD).
• In a transgenic HD mouse model, WA-induced heat-shock-response activation was associated with reduced mutant huntingtin aggregation and attenuation of selected disease-related abnormalities.
• Evidence for Nrf2/ARE activation, autophagy regulation, mitochondrial protection, and suppression of inflammatory signaling by WA is mostly derived from cellular and non-HD models, with limited validation in HD models.
• No clinical studies have yet demonstrated the safety or therapeutic efficacy of WA in HD patients, and important pharmacokinetic and toxicity parameters remain insufficiently characterized.

Clinical Significance

Citation

Kumari Risha, Gupta Vrinda, Devi Komalet al.. Neuroprotective Role of Withaferin A in Huntington's Disease: Current Evidence and Future Perspectives. Molecular neurobiology. 2026-Oct-17.